secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2022-06-28T23:59:59+00:00
Accession:  0001193125-22-183258
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant reports Q4 net loss $0.39, VTAMA approved, $2.1B cash, pipeline reprioritized
--------------------------------------------------------------------------------

- Net loss $291M in Q4 ($0.39/share); full-year net loss $924M ($1.26/share); revenue $9.2M Q4 vs $15.1M prior year.
- VTAMA (tapinarof) approved by FDA for plaque psoriasis in May; launch underway with 100+ person commercial team.
- Cash and equivalents $2.1B; company discontinued several programs including ARU-1801, DMVT-502/503/504.
- Melissa Epperly appointed to Board of Directors effective June 29, replacing Pat Machado.
- Pipeline milestones: Priovant initiated Phase 3 for brepocitinib in dermatomyositis; Immunovant Phase 3 in MG started.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000119312522183258/0001193125-22-183258-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000119312522183258/d372791d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-183258

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer